Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy
- First Online:
- 209 Downloads
Exenatide (Byetta®, Amylin Pharmaceuticals Inc., CA, USA) and sitagliptin (Januvia®, Merck & Co, NJ, USA) are two antidiabetic agents recently approved by the US Food and Drug Administration. The purpose of this analysis was to compare costs among patients with type 2 diabetes (T2D) treated with either of these agents.
Data with dates of service from September 1, 2005 through August 31, 2007, were obtained from a large US retrospective claims database. Intent-to-treat cohorts of adults diagnosed with T2D who began taking either exenatide (n=1885) or sitagliptin (n=2482) and did not use the alternate medication in the 6-month follow-up period were created. Six-month total medical costs were estimated using stepwise multivariate regressions. Six-month total diabetes-related medical costs, a component of total medical costs, were also estimated using stepwise multivariate regressions. In addition, other cost components were examined using either stepwise multivariate regressions or a two-part model that controlled for the probability of using the medical service. Smearing estimates were used to transform estimated log costs into costs. The analysis controlled for the potential impact of patient demographics, general health, prior resource use, comorbidities, and timing of treatment initiation.
Exenatide was associated with lower total 6-month direct medical costs ($9340 vs. $9995; P<0.0001), despite some component costs being slightly higher with exenatide: diabetes-related drug costs ($1765 vs. $1743; P=0.0062), diabetes-related medical costs ($4142 vs. $4002; P<0.0001), and emergency room costs ($43 vs. $29; P=0.0388). Exenatide was associated with lower outpatient costs ($4498 vs. $5942; P<0.0001).
Compared with the use of sitagliptin, exenatide was associated with lower total medical costs (difference of $655) despite higher total diabetes-related costs (difference of $140). As a result, there appears to be overall cost savings associated with the use of exenatide relative to sitagliptin.
Keywordsassociated costs exenatide sitagliptin total diabetes-related medical costs total medical costs type 2 diabetes
Unable to display preview. Download preview PDF.
- 4.Barclay L. Exenatide approved for type 2 diabetes: an expert interview with John B. Buse. Medscape Today. May 4, 2005. Available at: http://www.medscape.com/viewarticle/504227. Accessed June 18, 2008.
- 6.Nielsen LL, Okerson T, Holcombe J, Hoogwerf B. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diab Sci Tech. 2008;2:255–260.Google Scholar
- 9.Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239–1246.PubMedCrossRefGoogle Scholar
- 12.US Food and Drug Administration. FDA approves new treatment for diabetes: first in a new class of diabetes drugs. Available at: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01492.html. Accessed June 17, 2008.
- 19.Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, doubleblind, noninferiority trial. Diabetes Obes Metab. 2007;9:194–205.PubMedCrossRefGoogle Scholar
- 24.DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagons secretion, gastric emptying and caloric intake: a randomized, cross-over study. Curr Med Res Opin. 2008;24:2943–2952.PubMedCrossRefGoogle Scholar
- 33.Buse JB, Ginsberg HN, Bakris GL, et al. American Heart Association; American Diabetes Association. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care. 2007;30:162–172.PubMedCrossRefGoogle Scholar
- 34.Barnett AH, Burger J, Johns D, et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007;29:2333–2348.PubMedCrossRefGoogle Scholar
- 40.Brixner DI, Oderda GO, Ye X, Boye KS, Wintle M, Fabunmi R. Clinical effectiveness of exenatide in patients with type 2 diabetes in a primary care electronic medical record database. Diabetes. 2008;57:A135. AbstractGoogle Scholar
- 41.Schroeder B, Misurski D, Wade R, et al. Exenatide utilization and effectiveness in a health plan population. Diabetologia. 2008;51:S352. AbstractGoogle Scholar
- 42.Data assets: better data matters. i3 web site. Available at: http://www.i3global.com/DataAssets/. Accessed June 16, 2008.